A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study

Drugs Exp Clin Res. 2000;26(5-6):163-70. A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study. Doroshenko YM, Hodysh YY, Uglyanitsa KN, Nefyodov LI. Institute of Biochemistry, National Academy of Sciences, Grodno, Belarus. nef@biochem.belpak.grodno.by We developed a method using high-performance [url=http://en.wikipedia.org/wiki/Liquid_chromatography]liquid chromatography[/url] for the determination of the main fluorescent component of Ukrain, a novel antitumor and immune-stimulating drug. Our method was based on ion-pair separation of Ukrain from [url=http://en.wikipedia.org/wiki/Perchloric_acid]perchloric acid[/url] extracts using [url=http://en.wikipedia.org/wiki/Reversed-phase_chromatography]reversed-phase column[/url], buffer with high molarity (0.5 M potassium phosphate, pH 2.65), high concentration of ion-pair reagent in the mobile phase (10 mM [octylsulfonic acid) controlled temperature of the separation (45 degrees C) and detection by fluorescence (360/455 nm). Under the above conditions a peak of the main Ukrain compound was resolved from fluorescent peaks of the sum of alkaloids of Chelidonium majus L. although several peaks of alkaloids were retained in Ukrain as traces. The height of this main peak was nearly constant, while the alkaloid peaks varied depending on the series of the preparation; chelidonine and [url=http://en.wikipedia.org/wiki/Thiotepa]thio-triethylenephosphoramide[/url] gave no peaks. Analytical recovery for Ukrain from human plasma was 98.0 +/- 4.5%. Therefore, Ukrain possesses neither significant stable binding to plasma proteins nor adsorption in blood cells.